Detail-driven Research Assistant with background in executing complex experiments, data collection and analysis. Displayed strengths include strong analytical skills, proficiency in research methodologies and commitment to ensuring accuracy of data interpretation. Recognised for strong work ethic, adaptability, and exceptional interpersonal skills. Works effectively unsupervised or as part of a team. Previous work has led to valuable contributions towards scientific advancements, showcasing ability to excel at collaboration with peers from diverse, multidisciplinary backgrounds.
2021:
2015: CTx Outstanding Achievement Award: PRMT5 project
2010: Novartis Individual Award for outstanding effort and commitment on the CLiP Project
2010: Team Award for excellence and outstanding productivity for the CLiP project..
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Sharma S, et al. Cell Chem Biol. 2023 Oct 19;30(10):1191-1210.e20.
HBO1 is required for the maintenance of leukaemia stem cells.
MacPherson L. et al. Nature. 2020 Jan;577(7789):266-270.
Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Barretina J, eNature. 2019 Jan;565(7738):E5-E6.
Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.
Baell JB, et al. Nature. 2018 Aug;560(7717):253-257.
Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9. Phillipson LJ, et al. Med Chem. 2015 Oct 1;23(19):6280-96.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Barretina J,et al. Nature. 2012 Mar 28;483(7391):603-7.